Early-stage de-risking QATCH focuses on prescreening injectability and manufacturability of biopharmaceutical drugs at an early stage, presenting a sales opportunity to biotech sponsors seeking to de-risk preclinical programs and reduce delays in bringing medicines to patients.

Small team leverage With a lean team (2-10 employees) and a high-value, niche sensor technology, engage in targeted outreach to founders and decision-makers in venture-backed biotech startups and small biotech groups that may require external instrumentation and screening capabilities.

Prototype to pilot The technology aims to de-risk preclinical work with very small sample requirements (μLs), suggesting opportunities with CROs, contract developers, and academic collaborations looking for efficient screening tools during early drug development.

Tech-enabled sales QATCH’s use of cloud and analytics tools (AWS, Google Analytics, Piwik PRO) indicates receptiveness to digital engagement; tailor content and webinars demonstrating ROI and speed gains to attract interest from potential pharma partners and distributors.

Funding and growth signals Current revenue and modest funding imply readiness for strategic partnerships, licensing, or pilot collaborations rather than full-scale commercialization; target potential investors, co-development partners, and biotech incubators seeking novel sensor solutions.